←
OncoAlert128,121 posts
OncoAlert avatar✓

OncoAlert ✓

@OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

◷ Joined March 2019▧ 6,085 Photos and videos
OncoAlert avatar
OncoAlert@OncoAlert·Nov 16

🎸 #UromigosLIVE 2026: the conversation on X 📊 THE FINAL NUMBERS Coverage by @OncoAlert 🚨 Nashville | Nov 13–14 🌍 5.7M potential reach 💬 3,200 posts & mentions 🔥 4,200 engagements 🇺🇸 USA 59.5% 🇮🇹 Italy 13.3% 🇪🇸 Spain 10% 🇮🇳 India 4.6% 🇯🇵 Japan 🇩🇪 Germany 🇸🇦 Saudi Arabia 🇦🇪 UAE 🇳🇱 Netherlands 🏆 Thank you to every #UroVoice who amplified the meeting, and to Tom & Brian for an unforgettable #UromigosLIVE 🙏 WE ARE ALL OncoAlert 🌐 Source: Talkwalker, X, Nov 10–16 @Uromigos @tompowles1 @brian_rini @shilpaonc @nataliagandur @PGrivasMDPhD @weoncologists @neerajaiims @Dr_Aggen @NazliDizman @montypal @AmandaNizamMD @scserendipity1 @DrKarineTawagi @CParkMD @TiansterZhang @OncoReporte @dralsharm @crisbergerot @UroDocAsh @RenoHemonc

Post attachment
Sumanta K. Pal, MD, FASCO avatar
⟳ OncoAlert retweeted
Sumanta K. Pal, MD, FASCO@montypal·Oct 28

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

Post attachment
Yuji Miura avatar
⟳ OncoAlert retweeted
Yuji Miura@YujiMiura5·16h

徹子の部屋、的な😆

29:36
Oriol Mirallas MD avatar
⟳ OncoAlert retweeted
Oriol Mirallas MD@DrMirallas·Nov 17

🚀 Our review on Hippo–YAP/TEAD pathway is now out in Pharmacology & Therapeutics @Sciencedirect @Scopus We discuss the: 🧬 Biology 💊 Emerging drugs 🎯 Early clinical proof-of-concept ❌ Resistance mechanisms ☣️ Toxicities and where the field may go next Thanks Dr. Yap for the support and mentorship @UTMDAnderson and to the rest of co-authors for their great work Dr. Tan, Crous, Selvadurai and Lynch👏🏽 #YAP #TEAD #HippoPathway #CancerResearch #DrugDevelopment @OncoAlert @myESMO @_SEOM @ASCO 👇🏽👇🏽 Full article: sciencedirect.com/science/ar…

Post attachmentPost attachmentPost attachment
OncoAlert avatar
⟳ OncoAlert retweeted
OncoAlert@OncoAlert·Nov 13

🎥 T-cell engagers in renal cell carcinoma: is the sun finally coming out? At #UromigosLive 2026 in Nashville, @tompowles1 and @brian_rini discuss the CD3 x ENPP3 bispecific data @montypal presented at #ESMO26 : 🔹 ENPP3 is expressed on most clear cell and papillary RCC 🔹 ORR ~45% in heavily refractory, PD-1-pretreated #RCC, across 3 active dose levels 🔹 Benefit seen regardless of prior HIF inhibitor or TKI therapy 🔹 Requires step-up dosing. Main toxicities are early CRS (doses 1–2) and rash, because ENPP3 is also on skin mast cells. Both look manageable 🔹 Still open: durability and ENPP3 expression as a biomarker Why has #kidneycancer lagged behind prostate cancer and SCLC on T-cell engagers, and how does it catch up? Possible next steps: combinations with PD-1, a move to frontline, and other targets like CD70. Plus a detour to the 1998 World Cup final ⚽ ⭐️MIBC session Friday 1pm CT: guoncologynow.com/videos/uro… ⭐️World Cup Final 🌐 3:30pm CT: guoncologynow.com/videos/uro… @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan #OncoAlert #GUOnc #OncoX

5:26
OncoAlert avatar
OncoAlert@OncoAlert·13h

📣 Registration Now Open for #IKCSNA26 Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America, where a multidisciplinary community of leading experts from academia, clinical care, industry and advocacy come together to share ideas, explore emerging trends and shape the future of kidney cancer research and care. 🗓️ November 19–21, 2026 📍 Dallas, Texas 🏨 Renaissance Dallas Hotel Register 👉 kidneycancer.org/event/2026-… @KidneyCancer @LauraBukavinaMD @QingZhangLab @bergsa83 @mkbupathi @ADESAIONCMD @AmyLuckenbaugh @virajmaster @spsutkaMD @ChadTangMD @MVossMD @TiansterZhang @PavlosMsaouel @salvolarosa @GEVaughan1

1:27
Mirrors of Medicine avatar
⟳ OncoAlert retweeted
Mirrors of Medicine@mirrorsmed·Nov 16

Can ctDNA tell us who should get SBRT for oligoprogressive mCRPC? jamanetwork.com/journals/jam… Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial In this prespecified analysis of the phase 2 TRAP trial, 77 patients with oligoprogressive metastatic castration-resistant #ProstateCancer received SBRT while continuing an androgen receptor pathway inhibitor. ➡️Pre-SBRT ctDNA positivity was associated with significantly shorter progression-free survival: median 3.0 vs 7.8 months for ctDNA-negative patients. ✅These findings suggest ctDNA status may help identify patients most likely to benefit from SBRT while continuing ARPI therapy. @f_orlando_, @Dr_AJC, @nickva1, @y_suhughes, @FrancescaBZNY, @alison_tree, @AttardLab

Post attachment
Mirrors of Medicine avatar
⟳ OncoAlert retweeted
Mirrors of Medicine@mirrorsmed·22h

🚨 73.8% response rate in advanced TNBC: promising early data for pumitamig + nab-paclitaxel. thelancet.com/journals/lanon… Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial In this phase 1b/2 trial, first-line pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, plus nab-paclitaxel demonstrated encouraging activity in 42 patients with advanced or metastatic triple-negative #BreastCancer . ➡️ At 35.2 months’ median follow-up, the confirmed objective response rate was 73.8%, including one complete response. ➡️ Grade ≥3 toxicities included neutropenia, leukopenia, proteinuria, and febrile neutropenia. No treatment-related deaths occurred. ✅These findings support further evaluation in larger global trials.

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ OncoAlert retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Nov 13

🧬 Can urine EV glycan signatures help us distinguish aggressive prostate cancer from indolent disease BEFORE committing patients to biopsy? lnkd.in/exDkkJ4d Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer Could urine extracellular vesicle (EV) glycan profiling improve #ProstateCancer detection beyond PSA? ➡️ In this study of 135 men, Glycoflow analysis of post-DRE urine EVs improved discrimination of clinically significant prostate cancer (AUC 0.80 vs 0.71–0.72) and very significant disease (0.81–0.82 vs 0.72–0.73) when combined with clinical parameters. ✅ EV glycan profiling provided complementary diagnostic information, potentially improving biopsy decisions and reducing overdiagnosis, pending larger validation. @sim1garz8 @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ OncoAlert retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·20h

What if instead of simply inhibiting the androgen receptor, we could rewire the complex that drives its activity? nature.com/articles/s41586-0… Domain-alteration chimeras rewire oncogenic complexes in prostate cancer This study introduces DALTAC-1, a first-in-class domain-alteration chimera designed to rewire the androgen receptor (AR)–p300/CBP complex in metastatic castration-resistant #ProstateCancer . ➡️ By forcing a non-native interaction between AR and p300/CBP, DALTAC-1 locks the complex into a nonproductive state, profoundly suppressing AR-driven transcription. ✅The approach produced deep, durable tumor regressions across preclinical models while selectively targeting AR-dependent prostate cancer cells. @ArulChinnaiyan, @Chinnaiyanlab, @Pixel_and_Path, @abhijitparolia, @EyunniSanjana, @yuanyuan_qiao, @rahulmannan, @UMich @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Post attachment
Uromigos avatar
⟳ OncoAlert retweeted
Uromigos@Uromigos·18h

Can patients with muscle-invasive bladder cancer avoid radical cystectomy? From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸 Listen to the full discussion ⬇️ 🎧 Apple: apple.co/4t9r8Ps 🎧 Spotify: bit.ly/4iPpf6Q

Post attachment
OncoAlert avatar
OncoAlert@OncoAlert·18h

On November 17, 2026, the FDA 🇺🇸granted accelerated approval to neladalkib for adults with ALK-positive locally advanced or metastatic #NSCLC #LungCancer 🫁previously treated with alectinib, or with ≥2 ALK TKIs plus platinum chemotherapy. In the single-arm ALKOVE-1 trial, ORR was 49% after alectinib alone (n=67) and 32% after multiple TKIs and chemotherapy (n=155). Among responders, about half had responses lasting ≥12 months in both cohorts, offering a new option. Pinging Lung Cancer Faculty @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers

Post attachment